Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Head and Neck Neoplasms 1

Interventions

pembrolizumab 24Radiotherapy 21Cisplatin 21Cetuximab 13Carboplatin 11Paclitaxel 8Nivolumab 8durvalumab 7Radiotherapy, Intensity-Modulated 6Docetaxel 6Fluorouracil 5Cyclophosphamide 5zalutumumab 4Everolimus 4Amifostine 4spartalizumab 3fludarabine 3epacadostat 3cemiplimab 3Ipilimumab 3Immune Checkpoint Inhibitors 3Gefitinib 3Filgrastim 3Erlotinib Hydrochloride 3Celecoxib 3Capecitabine 3selpercatinib 2palbociclib 2fludarabine phosphate 2bintrafusp alfa protein, human 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Head and Neck Neoplasms × elgemtumab × Clear all
NCT02143622 2016-04-21

Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients

Novartis

Phase 1/2 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡